A wound healing agent

 

(57) Abstract:

The invention can be used in the production of pharmaceuticals and for the creation of a wound healing agent that stimulates the healing of wounds of various etiologies. The technical result - the development of a tool to stimulate the healing of indolent wounds, infected burns, necrotic ulcers and other purulent lesions of tissues. The composition of the medicinal product, wt. %: polymyxin M 0,15-0,2, novocaine 0,5-1,0, glycerin 8,0-12,0, anhydrous lanolin 2,0-4,0, distilled monoglycerides 1.5 to 2.5, abbasian of 0.8-1.0, butter fat (stone) 10,0-20,0, nipagin 0,11-0,12, nipazol 0,11-0,12 distilled water to 100.0. table 4.

The invention relates to medicine, can be used in the production of pharmaceuticals and relates to means for stimulating the healing of wounds of various etiologies.

It is known that polymyxin M applied topically for various slow purulent processes: vyalozazhivayuschih wounds, infected burns, necrotic ulcers, bedsores [1, 2], particularly those caused by gram-negative anaerobic bacilli, including Pseudomonas aeruginosa [7].

However, local application /wound/ polymyxin b M in the form of the solution is, the usage in the form of ointments on the basis of vaseline or gel methylcellulose as the basis is not optimal. So, for example, ointments on the basis of vaseline cause an increase in temperature of the skin areas to which they applied, violated the absorbability and excretory function of the skin, vaseline is not resorbed by the skin, clogged pores, reduces evaporation through the sweat pores, while the outer layer material and reduces the resistance of the skin [3]. Ointments on the basis of methylcellulose gels formed on the surface of the wound dense film, which painfully pulls wounds, impedes the outflow of pus, it is difficult to remove and biologically not destroyed [3].

The aim of the invention is to devise effective means of stimulating the healing of indolent wounds, infected burns, necrotic ulcers and other purulent lesions of the tissues caused by Escherichia coli and gram-negative microbes.

To achieve this goal in the drug entered the complex of active components, such as polymyxin M, novocaine, glycerin emulsion of oil and water stabilized by abbasides in the following ratio, wt.%:

Priscillianus - 1,5-2,5

Abbasian - 0,8-1,0

Oil fatty /stone/ - 10,0-20,0

Nipagin - 0,11-0,12

Nipazol - 0,11-0,12

Distilled water - Up to 100.0

The proposed solution allows you to create an effective, low-toxic, stable preparation. Introduction aubazidan bacterial polysaccharide - allows you to increase the resistance of the microorganism and its protective function of the skin [4]. In addition, it is shown that bacterial polysaccharides increase the resistance of the microorganism to the effect of toxic doses of drugs and tolerability polymyxin b, and procognitive the last action [5,6]. For rapid absorption and full commitment of medicinal substance - polymyxin b - used rational pharmaceutical form emulsion in which medicinal substances have a high degree of dispersion and therefore faster and better exhibit their therapeutic effect. In the form of emulsions also softens irritant effect of drugs on the patient's skin and mucous membranes of the body.

The inventive tool is obtained as follows. Weighed medicinal substance - novocaine, polymyxin M, abbasian, distilled monoglycerides, lanolin of babukhadia, to which is added pre-dissolved in water novocaine, polymyxin M, glycerin and nipagin. Then in the resulting solution, aubazidan with medicinal substances add the fraction containing distilled monoglycerides, oil oily /stone/, anhydrous lanolin and nipazol. The mixture emuleret at a temperature of 65-70oC with the help of a mixer for 2-3 minutes. The resulting system is passed through the homogenizer. The finished emulsion is cooled at a low speed mixer /60-100/min to ambient temperature /20oC/.

Example 1. In accordance with the letters N 1 /table 1/ abbasian /0.8 g/ are dissolved in parts of water distilled /30,0/. In the resulting solution, aubazidan add the pre-dissolved in the remaining amount of distilled water /46,85 g/ novocaine /0.5 g/, polymyxin M /0.15 g/ glycerol /8.0 g/ and nipagin /0.1 g/. Then the resulting solution of aubazidan with medicinal substances mixed with the fat fraction containing distilled monoglycerides /1.5 g/ butter fat /10.0 g, anhydrous lanolin 3 /2,0 g/ and nipazol /0.1 g/. The mixture emuleret at a temperature of 65-70oC with the help of a mixer for 2-3 minutes. The resulting system is passed through the homogenizer. The finished emulsion on the market 2-10 carried out analogously to example 1 and receive emulsion, the composition and properties of which are presented in tables 1 and 2.

The resulting cream is an emulsion system type "oil-water" on the basis of a polysaccharide, of soft consistency, which is very stable during the whole observation period /24 months/.

To establish changes under different storage conditions cream kept at temperatures 40oC, 20oC and 4oC. condition of the studied emulsion system before laying and during storage was determined by the following indicators: colloidal stability, dispersion, antimicrobial activity of antibiotics and preservatives, as well as viscous properties of the system as freshly prepared, and in the process of storing /24 months/. Studies of basic physical-chemical parameters of the system allow us to conclude that the claimed product has a high stability /table 2/.

Research on the effectiveness of the proposed tool was carried out in the treatment of purulent wounds in animals. The experiment was performed at 120 outbred rats-males weighing 150-190, All animals were divided into 4 groups of 30 animals each. Model festering wounds on sleep/ no additional impact on the wound had been received. Animals 2nd, 3rd and 4th groups were made appliques ointment drugs on wound at a dose of 0.5 g/cm2daily until complete wound healing: in the 2nd group inflicted polymyxinb ointment on the basis of vaseline, in the 3rd group-polymyxin M on the basis of methylcellulose gel, 4-Oh group of the inventive tool / concentration of polymyxin b M was 0.2 g per 100.0 g of the drug in all applied dosage forms/.

Was carried out planimetric control wound healing, recorded time necrolysis, resorption otolaryngolo infiltration, granulation, epithelialization of the wound. Morphological control was carried out using light microscopy sections /stained with hematoxilin and eosin, pikrofusin, methylene blue. Microbiological study of wound was performed by the standard technique 1 time in three days. All work was carried out in accordance with the Order of the USSR Ministry of health N 755 from 12.08.77 "About the humane treatment of experimental animals [9]. The obtained data statistically processed.

Experimental results are presented in tables 3 and 4. Statistically significant /compared to control/ reduce the average duration of the cleansing of wounds from necromantia control significantly earlier began epithelization of wounds, however, it was previously resolved colornews infiltration and appeared granulation only in the 4th group of animals /table 3/. The acceleration of the flow of reparative and regenerative processes in the festering wound achieved in the 3rd and 4th groups, however, significantly maximum intensity of it was in the 4th group of animals.

Data analysis microbiological studies have shown that the number of sterile crops discharge from wounds, starting with 4 days from start of treatment was significantly higher in the 4-Oh group, it is the leadership /see table 4/ continued until complete healing of wounds.

Given the above experimental data, it is possible to say that the inventive tool accelerates the healing of purulent wounds in animals due to active antimicrobial prolonged action, reduction of terms of cleansing wounds and inflammatory processes around it, stimulating the formation and maturation of granulation tissue activation epithelialization.

Sources of information

1. Navashin S. M., Fomin, I. P. Rational antibiotic therapy. -M, Medicine, 1982. - 49 S.

2. Chernomordik A. B. the Use of antibiotics and other chimiotherapie in ointments. - Tbilisi, Back To Text, 1979. - S.

4. Elin N. P., Arkadiev, E., vitovska, A., Gromov, E. G., Biological properties and chemical structure of the soluble glucan from Aureobasidium pullulans. - Proceedings of LHFI/Leningrad.chem. the pharmacist. in-t/, 1967, vol. 22. Some aspects of the biochemistry of microorganisms.

5. Shapovalov S. P. Influence of levomicetina and bruneomitsina combined them with prodigiozana on some non-specific defensive reactions of the organism with the grafted lymphadenosis, NC/Lee. Antibiotics, 1970, I. 16. -N 10. -S. 924-928.

6. Weisberg, E., Sacks, M. I. Treatment of microbial eczema by prodigiozana in combination with antibiotics. J. Antibiotics, 1968. -N6. - S. 553-555.

7. Manual medicine. Diagnosis and therapy. 2 T. Per. from English. Ed. P. Berko, E. Fletcher. - M.: Mir, 1997. - 1917 with.

8. Verai M. I., Hausman B. J., Denisov, I. N., Chumachenko P. A. Application of lasers in medicine. - M., 1985. Vol. 1/220/.- S. 21-22.

9. The order of the USSR Ministry of health N 755 from 12.08.77 "About the humane treatment of experimental animals."

A wound healing agent, including polymyxin M, characterized in that it additionally contains procaine, glycerin, lanolin anhydrous, distilled monoglycerides, abbasian, mA is mixin M - 0,15 - 0,2

Novocaine - 0,5 - 1,0

Glycerin - 8,0 - 12,0

Anhydrous lanolin - 2,0 - 4,0

Distilled monoglycerides and 1.5 - 2.5

Abbasian - 0,8 - 1,0

Oil fatty (stone) - 10,0 - 20,0

Nipagin - 0,11 - 0,12

Nipazol - 0,11 - 0,12

Distilled water Up to 100.0

 

Same patents:
The invention relates to medicine, in particular to composite medicines used for the treatment of skin diseases

The invention relates to therapeutic tools, specifically setidentityproviderid N-substituted nitrogenous heterocyclic compounds and methods of producing such compounds, intermediate products used in obtaining, compositions containing such compounds and the use of such heterocycles
The invention relates to medicine, in particular to pharmacology concerns the creation of tools for the treatment of skin diseases

The invention relates to methods for the care and protection of the skin of humans and animals and can be used in medical practice

The invention relates to chemical-pharmaceutical industry, in particular to the manufacture of medicinal phytoplank prolonged action for the prevention and treatment of inflammatory diseases of the mucous membrane and skin of the body, and immune disorders
The invention relates to medicine and pharmaceutical industry, in particular to methods for wound healing and antimicrobial agents from plant material

The invention relates to medicine and is a method of treating scar-modified tissue drug "Morical"

The invention relates to medicine, in particular to surgery, and may find wide use in practice, treatment of long-term healing of wounds and ulcers, accompanied by the emergence of eczematous contact dermatitis

The invention relates to iododerma biologically active compositions containing iodine and halides of nitrogenous bases of the formula I, where the values of the radicals a, b, C, R, X and m are specified in the claims

The invention relates to the field of pharmaceutical industry and relates to a physiologically compatible emulsions containing hydrides perftoruglerodnykh esters

The invention relates to an external preparation for topical application, in particular to the outer local drug use, containing as activitiesthese substance 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol or its pharmaceutically acceptable acid salt additive

The invention relates to the field of pharmacy and relates to a technology of pediatric dosage forms drug acid, methenamine, which has anti-inflammatory and antipyretic action /Belikov Century G

The invention relates to the field of pharmaceutical industry and relates to emulsions of the type oil-in-water containing propofol and edentate

The invention relates to medicine, can be used in the production of pharmaceuticals and concerns the establishment of a drug for the treatment of nonhealing infected ulcers and wounds

The invention relates to medicine, can be used in the production of pharmaceuticals and for the creation of tools for healing of purulent-necrotic wounds of different etiology

The invention relates to medicine, can be used in the production of pharmaceuticals and for the creation of funds - ascorbylpalmitate emulsion for the treatment of dermatoses

The invention relates to medicine, can be used in the production of pharmaceuticals and for the creation of funds - ascorbylpalmitate emulsion for the treatment of dermatoses

The invention relates to medicine, in particular to a gastroenterologist, and can be used to stop bleeding from gastroduodenal ulcers
Up!